Drugs / Doxorubicinin
last change Jan 2025 re-read 2 minutes ago

Doxorubicinin

Developed for
diffuse large B-cell lymphoma

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06760039 Comparator Jan 2025 → Aug 2028 expected diffuse large B-cell lymphoma Sun Yat-sen University Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Doxorubicinin Doxorubicinin intravenous drip” NCT06760039
Route Intravenous “Doxorubicinin intravenous drip” NCT06760039